Mantle cell lymphoma (MCL) is a relatively rare form of non-Hodgkin lymphoma that is biologically heterogeneous with several subtypes. The clinical course of the disease can be highly variable. Although MCL is aggressive in the majority of patients, some variants of the disease can be indolent.
Risk-stratification models based on biological and clinical features have been developed, and identification of prognostic biomarkers at the time of diagnosis is becoming standard of care.
Although advances in treatment have improved outcomes in MCL, tailored approaches are needed based on the biology of the disease. Studies with novel therapies incorporating prognostic factors and biomarkers of response are under investigation.
How much do you know about prognostic markers of MCL? Test your knowledge with this quick quiz.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ann S. LaCasce. Fast Five Quiz: Non-Hodgkin Lymphoma (NHL): TP53 in Mantle Cell Lymphoma - Medscape - Feb 08, 2023.